Takeda Oncology
Manufacturing · Massachusetts, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
40 Landsdowne St, Cambridge, Massachuset...Phone Number
(800) 390-5663Website
www.takedaoncology.comRevenue
$705.2 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Takeda Oncology
Founded in 1993 and located in Cambridge, Massachusetts, Takeda Oncology is the oncology specialty business unit of Takeda Pharmaceutical. Takeda Oncology develops and produces oncology therapies for patients around the world.Explore more
Takeda Oncology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Takeda Oncology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Takeda Oncology has new funding data
Check if Takeda Oncology has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Takeda Oncology recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Takeda Oncology
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Takeda Oncology had a recent Job posting/layoffs
Takeda Oncology, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Takeda Oncology launches new products
Website visits: Recent activity has been detected on your website
Check out if Takeda Oncology is spiking on competitors!
Recommended Actions
Find VP level buyers at Takeda Oncology
Find 3 more new buyers
Compare Similar Companies to Takeda Oncology
Compare insights from companies similar to Takeda Oncology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$1.4B
1K - 5K
Private
$18M
1992
SG
Sean GormanDirector, Business Planning & Operations Medical Office Chief & Chief Marketing Officer
Company Profile Activity
Activity Insights
Takeda Oncology is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Takeda Oncology is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Takeda Oncology.
Takeda Oncology Tech Stack
A closer look at the technologies used by Takeda Oncology
Most Recent Scoops
Open Position
Open Position
Hiring Plans
Takeda Oncology has more open roles in Legal than it has had at any time in the past 12 months. Technologies mentioned include: GEM, and Remote. Areas of expertise include: Regulatory Environment.
Hiring Plans
Open Position
Open Position
Takeda Oncology News & Media
Takeda präsentiert positive Primäranalyse der Phase-II-Studie OPTIC zu ICLUSIG® (Ponatinib) – Ergebnisse untermauern das Potenzial, die Lücken bei den Behandlungsoptionen für Patienten mit CML in der chronischen Phase zu schließen
OSAKA, Japan, und CAMBRIDGE, Massachusetts, USA--(BUSINESS WIRE)--Wie Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda“) heute mitteilte, werden die Daten der Primäranalyse der Phase-II-OPTIC-Studie (OPTIC für Optimizing Ponatinib Treatment In CML) in einem mündlichen Vortrag bei der 57. Jahrestagung der American Society of Clinical Oncology (ASCO) sowie in einem weiteren mündlichen Vortrag bei der 26. Jahrestagung der Europäischen Gesellschaft für Hämatologie (EHA) vorgestellTakeda presenta análisis primario positivo del estudio OPTIC de fase 2 de ICLUSIG® (ponatinib), que consolida la capacidad de resolver las deficiencias en la atención de la LMC en fase crónica
OSAKA, Japón y CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) anunció hoy que los datos del análisis primario del estudio de fase 2 OPTIC (Optimizing Ponatinib Treatment In CML) se presentarán en una sesión oral en el 57.o Congreso Anual de la Sociedad Americana de Oncología Clínica (ASCO) virtual y en una sesión oral en el 26.o Congreso Anual de la Asociación Europea de Hematología (EHA). El OPTIC es un estudio aleatorizado y abiTakeda apresentará análise primária positiva do ensaio OPTIC de Fase 2 do ICLUSIG® (ponatinibe) para reforçar capacidade de solucionar lacunas no atendimento do LMC em fase crônica
CAMBRIDGE, Massachusetts e OSAKA, Japão--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) anunciou hoje que os dados da análise primária do ensaio OPTIC (Optimizing Ponatinib Treatment In CML) de Fase 2 serão apresentados durante uma sessão oral no 57o encontro anual virtual da Sociedade Americana de Oncologia Clínica (ASCO) e em uma sessão oral no 26o encontro anual virtual da Associação Europeia de Hematologia (EHA). O ensaio OPTIC é um estudo contínuo, raTheseus Pharmaceuticals emerges from stealth with $100M Series B and Ariad veterans at the helm
Theseus Pharmaceuticals, led by a team of ex-Ariad executives, will target treatment-resistant cancers after emerging from stealth mode with $100 million in Series B funding.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Takeda Oncology
Sign Up For FreeTo access detailed company insights
Founded in 1993 and located in Cambridge, Massachusetts, Takeda Oncology is the oncology specialty business unit of Takeda Pharmaceutical. Takeda Oncology develops and produces oncology therapies for patients around the world.... Read More
